Eli Lilly Q2: Strong Results Further Strengthen The Investment Thesis

Eli Lilly remains a buy after Q2, with robust revenue growth and strong performance from Mounjaro and Zepbound. LLY raised 2026 revenue guidance to $85–87 billion, driven by volume gains despite price declines, and reinforced margin expansion. Retatrutide is a key medium-term catalyst, with a BLA submission planned for Q1 2027 and potential in new therapeutic areas. Valuation is attractive at 1.43x PEG, below sector and historical medians, offering a potential 23.7% upside as LLY continues to outperform. JHVEPhoto/iStock Editorial via Getty Images Investment Thesis I'm keeping a buy rating on Eli Lilly ( LLY ) stock after the Q2 results release. This article is the continuation of my initial coverage article published last year, and since then, the results have This article was written by Multiplo Invest 3.37K Followers Follow More than 7 years of experience in equity analysis in LatAm. We provide our clients with in-depth research and insights to help them make informed investment decisions. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.